Frontiers18d
Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer
Cancer Research Center, Department of Biological Sciences, Alabama State University, Montgomery, AL, United States Triple-negative breast cancer (TNBC) is distinguished by negative expression of ...
Business Insider22d
Omeros' Zaltenibart Gets Rare Pediatric Disease Designation From FDA For C3 Glomerulopathy
Zaltenibart is the most proximal inhibitor of the alternative pathway. It blocks mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway ...
BioSpace22d
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Zaltenibart is the most proximal inhibitor of the alternative pathway. It blocks mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway, stopping the ...
Frontiers22d
Unraveling the web of defense: the crucial role of polysaccharides in immunity
The MBL of the lectin-complement pathway and proteins from the alternative and conventional complement pathway are among the proteins in blood plasma that can recognize polysaccharide BRMs. As a ...